Kowa Fuchs Endothelial Corneal Dystrophy Study K-321-303

I'm Interested!

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase III
Conditions Being Studied:

Study Purpose

The purpose of this study is for those that have Fuchs Endothelial Corneal Dystrophy (FECD) and are planning to have cataract surgery and a procedure called descemetorhexis. The main goal of this study is to find out the effect of K-321 on how long it takes for your eyesight to improve during the first 12 weeks after cataract surgery and descemetorhexis.